Compare EVC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | GALT |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 232.3M |
| IPO Year | 2000 | N/A |
| Metric | EVC | GALT |
|---|---|---|
| Price | $2.73 | $5.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 335.2K | ★ 390.3K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,178,000.00 | N/A |
| Revenue This Year | $64.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.96 | N/A |
| 52 Week Low | $1.58 | $0.73 |
| 52 Week High | $3.15 | $6.66 |
| Indicator | EVC | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 53.34 |
| Support Level | $2.75 | $5.31 |
| Resistance Level | $2.85 | $5.88 |
| Average True Range (ATR) | 0.11 | 0.50 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 60.94 | 38.46 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.